Renalytix PLC

Renalytix plc will revert to filing as a foreign private issuer (FPI) with the SEC, effective January 1, 2025, after a period of filing as a domestic reporting company.

Renalytix plc successfully passed all resolutions at its Annual General Meeting held on December 19, 2024, including the adoption of the 2024 UK Annual Report and the authorization for the issuance of new shares.

Renalytix plc has amended its 8-K filing to provide revised information regarding a private placement of ordinary shares and the restructuring of certain indebtedness.

Renalytix plc successfully passed all resolutions at its Extraordinary General Meeting, including those related to a capital raise, and appointed a new director while also announcing the resignation of a board member.

Renalytix has successfully raised $11.8 million through a placing and subscription, restructured its debt, and announced plans to delist from Nasdaq to move to the OTCQX market.

Renalytix has been granted an extension until October 25, 2024, to regain compliance with Nasdaq listing requirements and will transfer to the Nasdaq Capital Market effective August 27, 2024.

Renalytix's Q1 2025 report shows a decrease in net loss and operating expenses, alongside a strategic shift towards commercial sales activities and a recent capital raise.

Renalytix's Q3 2024 results show a decrease in revenue and ongoing losses, alongside significant cost reductions and a strategic review process.

Renalytix reports a decrease in revenue and increased net losses for the second quarter of fiscal year 2024, while also addressing Nasdaq compliance issues and implementing cost reduction measures.

Renalytix reports significant progress in commercializing its KidneyIntelX test, including FDA authorization, Medicare coverage, and cost reductions, projecting profitability within two years.

Icahn School of Medicine at Mount Sinai acquired 13,366,750 Ordinary Shares of Renalytix plc in a private placement, increasing its holdings.

Interim Chief Financial Officer of Renalytix plc, Joel R Jung, reports acquisition of employee stock options.

Icahn School of Medicine at Mount Sinai acquired 9,360,374 Ordinary Shares of Renalytix plc as part of the second tranche of a private placement.

Renalytix plc has scheduled its 2024 Annual General Meeting for December 19, 2024, to address key resolutions including financial reports, director compensation, auditor appointments, and share authorizations.

Renalytix is convening a General Meeting on October 31, 2024, to seek shareholder approval for resolutions including share allotment, director appointment, and disapplication of pre-emption rights to support the company's fundraising and strategic initiatives.

Renalytix plc is convening a general meeting on April 22, 2024, to seek shareholder approval for resolutions related to share allotment and disapplication of pre-emption rights to bolster the company's financial position and strategic flexibility.

Jefferson River Capital and related entities have reduced their beneficial ownership in Renalytix plc to below the 5% threshold.

UBS Group AG has filed an amendment to its Schedule 13G for Renalytix plc, primarily to correct the 'Date of Event Which Requires Filing of this Statement' to March 31, 2025.

UBS Group AG has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Renalytix plc, with its stake reduced to 0.0% as of the event date.

UBS Group AG has disclosed a 5.06% beneficial ownership stake in Renalytix plc, holding 16,774,708 ordinary shares, primarily due to its acquisition of Credit Suisse Group AG.